Bain Capital Life Sciences Investors, LLC Savara Inc Transaction History
Bain Capital Life Sciences Investors, LLC
- $557 Million
- Q3 2024
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Savara Inc stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 14,565,457 shares of SVRA stock, worth $42.8 Million. This represents 11.08% of its overall portfolio holdings.
Number of Shares
14,565,457
Previous 14,565,457
-0.0%
Holding current value
$42.8 Million
Previous $58.7 Million
5.21%
% of portfolio
11.08%
Previous 12.01%
Shares
4 transactions
Others Institutions Holding SVRA
# of Institutions
129Shares Held
158MCall Options Held
67.6KPut Options Held
29.4K-
Nea Management Company, LLC Timonium, MD24.5MShares$71.9 Million7.93% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$36.3 Million6.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.62MShares$25.4 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.16MShares$24 Million1.86% of portfolio
-
Vestal Point Capital, LP New York, NY8.09MShares$23.8 Million2.6% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $335M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.